Featured Research

from universities, journals, and other organizations

Interferon Or Surgery For Eye Surface Cancer – Which Is Best?

Date:
August 1, 2008
Source:
American Academy of Ophthalmology
Summary:
Scientists evaluated 29 patients who were treated within a 10-year period for ocular surface squamous neoplasia (OSSN), a type of cancer, either by surgical removal of the tumor or with topical interferon (alfa-2b).

James Chodosh, MD, and colleagues evaluated 29 patients who were treated within a 10-year period for ocular surface squamous neoplasia (OSSN), a type of cancer, either by surgical removal of the tumor or with topical interferon (alfa-2b).

There were no statistically significant differences in age, gender-affected eye and tumor size between patients in the two groups. Risk factors for this form of cancer include advanced age, light skin, extensive UV-light exposure, smoking, and exposure on the job to petroleum products. HPV (human papilloma virus) and HIV have also been associated with higher rates of OSSN.

Fourteen of the study patients opted for surgical excision; in all cases an aggressive removal of the tumor, with wide and deep margins around the tumor site, was followed by cryotherapy. The aggressive approach was used because more conservative excisions had been associated with high OSSN recurrence rates in other patients.

This is the first report on results of this aggressive approach. Eight study patients received simultaneous reconstruction of the ocular surface using amniotic membrane. Fifteen study patients were treated with interferon; two of these did not respond to treatment and were treated surgically. All patients in both treatment groups eventually experienced complete resolution of their OSSN without recurrence, and with no significant side effects of treatment in either group. Dr. Chodosh says these results suggest that "topical interferon alfa-2 b and aggressive surgical excision can both be considered effective treatments for OSSN."

This research was published in the August issue of Ophthalmology.


Story Source:

The above story is based on materials provided by American Academy of Ophthalmology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Ophthalmology. "Interferon Or Surgery For Eye Surface Cancer – Which Is Best?." ScienceDaily. ScienceDaily, 1 August 2008. <www.sciencedaily.com/releases/2008/08/080801152131.htm>.
American Academy of Ophthalmology. (2008, August 1). Interferon Or Surgery For Eye Surface Cancer – Which Is Best?. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/08/080801152131.htm
American Academy of Ophthalmology. "Interferon Or Surgery For Eye Surface Cancer – Which Is Best?." ScienceDaily. www.sciencedaily.com/releases/2008/08/080801152131.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins